In the pivotal PULSAR and PHOTON trials, it was found to be as effective with either 12- or 16-week dosing as the original 2 mg Eylea formulation, which needs to be injected every eight weeks ...

In terms of study design itself, the PULSAR trial recruited treatment-naive patients with neovascular AMD, and these patients were randomly assigned 1:1:1 to EYLEA 2 mg given every 8 weeks, EYLEA 8 mg ...

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have ...

Pharmacokinetic analysis showed that the CSF to free plasma osimertinib ratio was 22%. Most safety profiles were grade 1 and 2. Treatment with 80 mg once daily osimertinib achieved a median OS of 15.0 ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

The data from the phase 2 PRISM study comes from a cohort of 51 ... a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer ...

When is the Hades 2 release date? The mythological roguelike game was revealed during The Game Awards 2022. Despite receiving critical praise for their previous titles, Hades 2 is the first sequel ...

An SGLT2 inhibitor combined with a nonsteroidal mineralocorticoid receptor antagonist quickly cut urinary ...